1. Home
  2. MNMD vs NFE Comparison

MNMD vs NFE Comparison

Compare MNMD & NFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNMD
  • NFE
  • Stock Information
  • Founded
  • MNMD 2019
  • NFE 2014
  • Country
  • MNMD United States
  • NFE United States
  • Employees
  • MNMD N/A
  • NFE N/A
  • Industry
  • MNMD Pharmaceuticals and Biotechnology
  • NFE Oil/Gas Transmission
  • Sector
  • MNMD Health Care
  • NFE Utilities
  • Exchange
  • MNMD Nasdaq
  • NFE Nasdaq
  • Market Cap
  • MNMD 709.9M
  • NFE 773.2M
  • IPO Year
  • MNMD N/A
  • NFE 2019
  • Fundamental
  • Price
  • MNMD $9.61
  • NFE $2.63
  • Analyst Decision
  • MNMD Strong Buy
  • NFE Strong Buy
  • Analyst Count
  • MNMD 7
  • NFE 6
  • Target Price
  • MNMD $24.71
  • NFE $8.92
  • AVG Volume (30 Days)
  • MNMD 1.1M
  • NFE 22.1M
  • Earning Date
  • MNMD 11-06-2025
  • NFE 11-06-2025
  • Dividend Yield
  • MNMD N/A
  • NFE N/A
  • EPS Growth
  • MNMD N/A
  • NFE N/A
  • EPS
  • MNMD N/A
  • NFE N/A
  • Revenue
  • MNMD N/A
  • NFE $2,006,240,000.00
  • Revenue This Year
  • MNMD N/A
  • NFE $7.43
  • Revenue Next Year
  • MNMD N/A
  • NFE $8.38
  • P/E Ratio
  • MNMD N/A
  • NFE N/A
  • Revenue Growth
  • MNMD N/A
  • NFE N/A
  • 52 Week Low
  • MNMD $4.70
  • NFE $1.26
  • 52 Week High
  • MNMD $11.02
  • NFE $16.66
  • Technical
  • Relative Strength Index (RSI)
  • MNMD 53.63
  • NFE 57.65
  • Support Level
  • MNMD $8.70
  • NFE $1.28
  • Resistance Level
  • MNMD $10.04
  • NFE $2.85
  • Average True Range (ATR)
  • MNMD 0.50
  • NFE 0.29
  • MACD
  • MNMD 0.00
  • NFE 0.09
  • Stochastic Oscillator
  • MNMD 73.88
  • NFE 85.41

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

About NFE New Fortress Energy Inc.

New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.

Share on Social Networks: